Key facts
- This page summarizes Robert A. Eckert's Form 4 filing for AMGEN INC (AMGN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 Aug 2022, 18:16.
Robert A. Eckert - 18 Aug 2022 Form 4 Insider Report for AMGEN INC (AMGN)
- Reporting relationship
- Director
- Issuer ticker
- AMGN
- Reported as of
- 18 Aug 2022
- Net transaction value
- -$1,643,378
- SEC form
- 4
- Accepted by SEC
- 19 Aug 2022, 18:16:30 UTC
- Prior SEC filing
- 18 Aug 2022
- Next SEC filing
- 23 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrea A. Robinson, Attorney-in-Fact for Mr. Eckert
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert A. Eckert filed Form 4 for AMGEN INC (AMGN) on 19 Aug 2022.
Change
- Previous filing in this sequence was filed on 18 Aug 2022.
- Current net transaction value: -$1,643,378.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMGN
transaction
Common Stock
Sale
- Transaction value
- $1,643,378
- Shares
- -6,600
- Change %
- -24%
- Price
- $249.00
- Shares after
- 21,184
- Date
- 18 Aug 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported is an average price. The prices ranged from $248.73 to $249.19 per share. Full information regarding the number of shares purchased at each separate price within such range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
Footnote F2
These shares include 2,008 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.